Literature DB >> 30016119

Management and treatment of deep vein thrombosis in special populations.

Gudula Boon1, L F Van Dam1, F A Klok1, M V Huisman1.   

Abstract

INTRODUCTION: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most frequent cardiovascular disease besides myocardial infarction and stroke. Because DVT may cause life-threatening conditions, treatment should be started as soon as possible. This comprises certain challenges in special populations. Areas covered: In cancer-associated VTE, current treatment is different from non-cancer VTE due to disease-related interventions and higher bleeding risks. In the treatment of patients with extensive DVT, the role of catheter-directed thrombolysis has been investigated in two randomized trials, but results do not yield a recommendation for standard thrombolysis. The diagnosis of suspected recurrent DVT is especially challenging in case of ipsilateral DVT. Treatment strategies in recurrent DVT are dependent on the case and on particular risk factors. Also discussed is the therapy for DVT in pregnant women, which is more complex as a result of anticoagulants crossing the placenta. Expert commentary: DVT treatment in special populations poses special challenges due to high thrombotic and bleeding risk. This will be discussed in more detail in this review.

Entities:  

Keywords:  Deep vein thrombosis; cancer; extensive; pregnancy; recurrence

Mesh:

Year:  2018        PMID: 30016119     DOI: 10.1080/17474086.2018.1502082

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  6 in total

1.  MiR-205 promotes endothelial progenitor cell angiogenesis and deep vein thrombosis recanalization and resolution by targeting PTEN to regulate Akt/autophagy pathway and MMP2 expression.

Authors:  Li-Li Sun; Lun Xiao; Xiao-Long Du; Lei Hong; Cheng-Long Li; Jian Jiao; Wen-Dong Li; Xiao-Qiang Li
Journal:  J Cell Mol Med       Date:  2019-10-21       Impact factor: 5.310

Review 2.  Supportive medication in cancer during pregnancy.

Authors:  Flora Zagouri; Nikolaos Dedes; Alkistis Papatheodoridi; Michael Liontos; Meletios Athanasios Dimopoulos
Journal:  BMC Pregnancy Childbirth       Date:  2020-12-01       Impact factor: 3.007

3.  Application of Nursing Outcome-Oriented Integrated Zero-Defect Nursing Combined with Respiratory Function Training in Long-Term Bedridden Patients Undergoing Stroke.

Authors:  Shaona Xu; Yanan Yu; Hongling Liu; Weiwei Qiu; Yu Tang; Ying Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-30       Impact factor: 2.650

4.  Long noncoding RNA TUG1 induces angiogenesis of endothelial progenitor cells and dissolution of deep vein thrombosis.

Authors:  Yaping Feng; Bo Lei; Huan Zhang; Luyuan Niu; Xiangtao Li; Xiaoyun Luo; Fuxian Zhang
Journal:  Thromb J       Date:  2022-09-26

5.  LncRNA GUSBP5-AS promotes EPC migration and angiogenesis and deep vein thrombosis resolution by regulating FGF2 and MMP2/9 through the miR-223-3p/FOXO1/Akt pathway.

Authors:  Li-Li Sun; Feng-Rui Lei; Xu-Dong Jiang; Xiao-Long Du; Lun Xiao; Wen-Dong Li; Xiao-Qiang Li
Journal:  Aging (Albany NY)       Date:  2020-03-10       Impact factor: 5.682

Review 6.  Updated recommendations for the treatment of venous thromboembolism.

Authors:  Junshik Hong; Seo-Yeon Ahn; Yoo Jin Lee; Ji Hyun Lee; Jung Woo Han; Kyoung Ha Kim; Ho-Young Yhim; Seung-Hyun Nam; Hee-Jin Kim; Jaewoo Song; Sung-Hyun Kim; Soo-Mee Bang; Jin Seok Kim; Yeung-Chul Mun; Sung Hwa Bae; Hyun Kyung Kim; Seongsoo Jang; Rojin Park; Hyoung Soo Choi; Inho Kim; Doyeun Oh
Journal:  Blood Res       Date:  2021-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.